FDA designates orphan drug for mesothelioma treatment

The U.S. Food and Drug Administration (FDA) has given “orphan drug” status to a new medication called defactinib, which is being developed to treat mesothelioma. An orphan drug status is given to a type of medication with the potential to treat rare diseases, if proven effective in clinical trials.

A defactinib trial will involve 350-400 patients throughout 11 countries. The FDA will assist in setting up the trial and will waive any fees associated with the trial in hopes of inspiring more research into cures for mesothelioma.

Mesothelioma cancer is a rare disease that attacks the lungs or abdominal cavity. Mesothelioma is directly linked to asbestos exposure and can take decades to develop after initial contact. Thousands of patients have filed mesothelioma lawsuits after their employers exposed them to asbestos on the job.